- Who Were the Biggest Winners And Losers This Year?
- GE, Comcast Complete Deal Over NBC Universal: Source
- US May Raise Rates Before Jobs Recover: Fed's Plosser
- Stocks Likely Don't Need Santa to Keep Rally Going
- Larry Kudlow's Open Letter to Tiger Woods
- AIG Slashes US Debt Under Deal With New York Fed
- Seamstress Fined $5.7 Million for Insider Trading
- Super Fantasy Christmas Gifts of 2009
- Commercial Property Fears Are Overblown: Zell, LeFrak
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Predictions 2010: Technology
- Predictions 2010: Consumers
- Predictions 2010: The Big Picture
Text Size 
U.S. health regulators are seeking stronger warnings about the risk of pancreatitis after the deaths of two patients taking Amylin Pharmaceuticals' injectable diabetes drug Byetta, sending the company's shares down as much 16 percent.
 |
CNBC.com |
The Food and Drug Administration Monday said it had received six reports of hemorrhagic or necrotizing pancreatitis requiring hospitalization. Two of the patients died and the four others were recovering at the time of the reports.
The FDA said it was working with Amylin "to add stronger, more prominent warnings in the product label." Amylin co-markets the drug—one of the most successful new diabetes medicines in recent years—with Eli Lilly.
Amylin's shares [AMLN
Loading...
()
] were down about 15 percent at $28.95 in afternoon trading on the Nasdaq, while Eli Lilly's shares [LLY
Loading...
()
] fell 1.7 percent to $47.92 on the New York Stock Exchange.
Pancreatitis is an inflammation of the pancreas, which helps aid in digestion by releasing vital hormones. The condition usually subsides quickly, according to the Merck Manual of Medical Information.
Complications or death are rare, Amylin and Lilly said in a statement. Rates of such problems are about as common in patients taking the drug as in others who have pancreatitis.
In October, the FDA said it had reviewed 30 reports of pancreatitis in patients being treated with Byetta. At the time, Amylin agreed to add information about the risk on its drug label and to alert doctors about the problem.
It was not immediately clear if the FDA would order new so-called "black box'' warnings, the strongest type available, and representatives for the agency could not immediately be reached.
The companies said they would work with the agency to update the drug's label.
Print
Email
- Will the Fed raise rates? Will the dollar continue its slide? CNBC experts weigh in on the year ahead.
- Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
- Do you have what it takes to run your own business? Ask yourself these questions.
- Heavily armed pirates in Somalia have set up a sort of stock exhange to fund their hijackings.
- Since its launch in 1998, Google has become a primary force on the Internet. How much do you know about the company?
- A famed author has written all his work on an old typewriter that is now up for auction. The NYT reports.
Data is a real-time snapshot *Data is delayed at least 15 minutes